ORBIT-AF II Patient
The purpose of this registry is to better understand how patients diagnosed with an abnormal heart rhythm called Atrial Fibrillation or A-Fib are cared for by their health care provider and what happens to them as a result of the care they receive, and in particular, the drug therapy they receive and their associated outcomes.
Being enrolled in this observational registry means that a patient will be cared for just as if they were not enrolled, however, information will be gathered from the patient and their health-care provider. Approximately 15,000 men and women, ages 21 years or older, who are newly diagnosed with A-Fib or have had A-Fib and are being treated with the newer anti-coagulant drugs are expected to participate. The patients would be followed for 2 years. The study is being sponsored by Janssen Scientific Affairs, LLC.
Contact:
Rhode Island Hospital
Cardiac Projects Office
401-444-5324
- Our Services
- Meet the Team
- Patient Stories
-
Cardiovascular Research
-
Cardiovascular Institute Current Studies
- Absorb III Patient
- Absorb III Physician
- SILVER-AMI Study Patient
- SILVER-AMI Study Physician
- Secret Trial Patient
- Secret Trial Physician
- Lutonix Patient
- Lutonix Physician
- ORBIT-AF II Patient
- ORBIT-AF II Physician
- RenalGuard Trial Patient
- RenalGuard Trial Physician
- Ischemia Study Patient
- Ischemia Physician
- Mind Your Heart Study II
- Clinical and Translational Research Center
- Research Interests
-
Cardiovascular Institute Current Studies
- Lifespan Cardiovascular Institute Awards and Certifications
- Schedule an Appointment at the Lifespan Cardiovascular Institute
- Heart Health and Exercise
- What Are the Symptoms of a Heart Attack?
- Best Heart Health Foods
- Giving to the Lifespan Cardiovascular Institute
- The Lifespan Cardiovascular Institute in the News